MINI LONG - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 18:27:31 20/05/2024 BST | ||
| 20.21 EUR | +1.86% |
|
| Current month | +28.56% | ||
| 1 month | +27.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 20/05/24 | 20.21 | +1.86% |
| 17/05/24 | 19.84 | +2.37% |
| 16/05/24 | 19.38 | 0.00% |
| 15/05/24 | 19.38 | +6.60% |
| 14/05/24 | 18.18 | -2.15% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 06:27 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KF6APH |
| ISIN | DE000KF6APH0 |
| Date issued | 13/12/2021 |
| Strike | 228.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.68 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.73 € |
|---|---|
| Lowest since issue | 1.52 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.9
USD
Average target price
462.6
USD
Spread / Average Target
+3.74%
- Stock Market
- Certificates
- Certificat
